Newsletters
- All
- AMR Action Fund
- Can you help?
- CARB-X
- CDC
- FDA
- Government Action
- Jobs
- Meetings
- PK & PK-PD
- Push/Pull
- R&D Insight
- RFPs
- Something Different
- Summaries
- Wellcome Trust
- WHO
- Wonkish
All
- All
- AMR Action Fund
- Can you help?
- CARB-X
- CDC
- FDA
- Government Action
- Jobs
- Meetings
- PK & PK-PD
- Push/Pull
- R&D Insight
- RFPs
- Something Different
- Summaries
- Wellcome Trust
- WHO
- Wonkish
Help Alan Carr with a point survey on COVID-19 vaccines!
29 September 2020
Dear All, Once again, we’re going to have a brief change from our usual programming with this newsletter. I hope you ...
Read More >
In Praise of Non-Inferiority
19 September 2020
Dear All (wonkish but intended for everybody to read and absorb): 27 Jan 2021 update: This topic now has its ...
Read More >
FDA and EMA regulatory updates / Fireside chat during the 4th AMR Conference
14 September 2020
Dear All (lots and lots of wonkish detail here, be sure your blood caffeine level is adequate!), During the 24-28 Aug ...
Read More >
Treating resistant Gram-negatives: IDSA provides pragmatic expert advice
9 September 2020
Dear All, IDSA (Infectious Diseases Society of America) have today released an eagerly awaited new guidance document on treating infections ...
Read More >
New antibiotics are not being registered or sold in Europe in a timely manner
7 September 2020
Dear All (and with thanks to Kevin for leading the charge on this newsletter), While listening to last week’s BEAM-sponsored ...
Read More >
Dame Sally and #RescueTheLobster: Meetings past and present worth your time
3 September 2020
Dear All, There’s a tidal wave of meetings for you to note! Some have already occurred but can easily be ...
Read More >
Reimbursing for innovative antibiotics / Encouraging updates from the AMR conference
1 September 2020
Dear All (with thanks to Kevin as the lead author on this note and also with a wonkish note alert ...
Read More >
EMA Network Strategy to 2025: Action on AMR / Comments due 4 Sep
26 August 2020
Dear All, We learned today during the BEAM AMR conference (link) that EMA released a call on 7 June 202 for ...
Read More >
Global AMR Hub launches Incentives Gallery / AMR Conference is underway
25 August 2020
Dear All, In case you missed it, the 4th AMR Conference sponsored by BEAM, CARB-X, Novo REPAIR, Wellcome Trust, the ...
Read More >
Alan Carr’s August ’20 Antibiotic-Antifungal update: Required reading!
14 August 2020
Dear All, I hope everyone is finding a bit of time to go off-line during August … always a good ...
Read More >
Important WHO job opportunity: Global governance structures for AMR-related work
8 August 2020
Dear All, Just below my signature, you will find the details of WHO’s search for a consultant to help them ...
Read More >
Final FDA LPAD guidance: Same substance, useful clarifications
6 August 2020
Dear All, FDA have released the final version of their LPAD (Limited Population Pathway for Antibacterial and Antifungal Drugs, really ...
Read More >
Beyond the AMR Action Fund: PBS NewsHour and Things for us all to do!
3 August 2020
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), While we’re all thrilled with the announcement of ...
Read More >
Estimating attributable mortality of resistant bloodstream infections: GLASS (WHO) recommended method
20 July 2020
Dear All, WHO’s GLASS Secretariat (Global Antimicrobial Resistance Surveillance System, link) have recently released a standardized method for estimating attributable ...
Read More >
Plazomicin EU marketing application is withdrawn: Near zero market value of newly approved antibacterials
11 July 2020
Dear All (with thanks to Kevin Outterson for co-authoring this newsletter), Last week’s announcement of the AMR Action Fund was ...
Read More >
AMR Action Fund: A $1b down payment from Industry; A call for creation of strong Pull incentives
9 July 2020
“The world is changed by your example, not by your opinion” (Paulo Coelho) Dear All, The AMR Action Fund (https://www.amractionfund.com/) ...
Read More >
Draft FDA guidance on anti-infectives for children: It’s (mostly) all about PK and safety
7 July 2020
Dear All (wonkish alert … the first 3 segments are non-wonkish but the last 2 are in the wonkish zone ...
Read More >
FDA: Early endpoints and late endpoints suggest a path to global regulatory convergence (Bart et al.)
5 July 2020
Dear All (wonkish note alert … top-up your coffee and settle in!), Today we have a tour of a recent ...
Read More >
FDA analysis of 40-years of antibacterial development: Dheman et al.
30 June 2020
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), Just out in CID is a paper in ...
Read More >
SPIDAAR & ATLAS: Data sharing via AMR Surveillance partnerships
29 June 2020
Dear All, Building on the ATLAS database (link) that provides open access to data from 2004 to the present out ...
Read More >